Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Tauopathies 2Neurodegenerative Diseases 2Nervous System Diseases 2Mental Disorders 2Inflammation 2Dementia 2Central Nervous System Diseases 2Brain Diseases 2Alzheimer Disease 2Neurocognitive Disorders 1Cognitive Dysfunction 1

Interventions

Dexamethasone 4XENP 1595 2Electroencephalography 2selinexor 1pomalidomide 1ixazomib 1fasudil 1birtamimab 1UE2343 1Telemedicine 1Tablets 1Standard of Care 1Rosiglitazone 1Propofol 1Positron-Emission Tomography 1Methods 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hypnosis 1Hormones 1Exercise 1Ethanol 1Donepezil 1Cyclophosphamide 1Control Groups 1Calcium Dobesilate 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Alzheimer Disease × XENP 1595 × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡